Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage

Tigress Financial Maintains Neutral on Pershing Square, Raises Price Target to $41

Wells Fargo Maintains Equal-Weight on Pershing Square, Raises Price Target to $36

QUICK SPARK: Microsoft's AI Spending Pays Off With Azure Growth Set to Reach 45%

Bank of America reiterates Microsoft stock with a Buy rating and raises its price target from $500 to $600.

QUICK SPARK: Michael Burry Highlights Same AI 'Terminator Risk' as Bill Ackman

Michael Burry recommends reading the recent post from Dwarkesh Patel on AI agent security incidents at OpenAI.

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report